Sixfold Bioscience has developed a patented technology for the safe and effective drug delivery of cell and gene therapeutics. Its programmable oligonucleotide delivery system (PODS) provides a cost-effective way to deliver a diverse range of therapeutic cargo with high targeting specificity.
There is currently a lack of safe, efficient in vivo delivery systems for cell and gene therapeutics. Many cell and gene therapies show great potential for achieving this, but their wide implementation has been limited by both complex and expensive manufacturing processes, and an inefficiency in reaching their targets. PODS is an efficient, non-viral, RNA-based drug delivery technology that has shown promising early in vitro and in vivo results.
Based at the Translation and Innovation Hub at Imperial College London, Sixfold Bioscience has been awarded funding by Innovate UK to support two projects that will help in accelerating the pre-clinical development of the PODS platform.
Anna Perdix Rosell, Co-founder and Chief Scientific Officer, leads Sixfold Bioscience’s R&D team and is helping to devise its long and short-term strategy for preclinical research. Supported by the SME Leaders Programme, she aims to strengthen skills in strategic product development to support Sixfold’s goal of revenue generation through pharmaceutical collaboration. This will help the company make an impact on the global drug delivery systems market which is currently valued at £/$3.2 billion and is projected to rapidly grow.
Visit Sixfold Bioscience's website here.
